Abstract:Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced malignancies, including non-small cell lung cancer (NSCLC). These agents have improved clinical outcomes and have become quite an attractive alternative alone or combined with other treatments. Although ICIs are tolerated better, they also lead to unique toxicities, termed immune-related adverse events (irAEs). A reconstituted immune system may lead to dysregulation in normal immune self-tolerance and cause inflammatory side effects (irAEs). Although any organ system can be affected, immune-related adverse events most commonly involve the gastrointestinal tract, endocrine glands, skin, and liver. They can occur anytime during the treatment course and rarely even after completion. Owen and colleagues showed that approximately 30% of patients with NSCLC treated with ICIs develop irAEs. Kichenadasse et al. conducted a thorough evaluation of multiorgan irAEs, which is of particular interest because information regarding these types of irAEs is currently sparse. It is important to delineate between infectious etiologies and symptom progression during the management of irAEs. Close consultation with disease-specific subspecialties is encouraged. Corticosteroids are the mainstay of treatment of most irAEs. Early intervention with corticosteroids is crucial in the general management of immune-mediated toxicity. Grade 1–2 irAEs can be closely monitored; hypothyroidism and other endocrine irAEs may be treated with hormone supplementation without the need for corticosteroid therapy. Moderate- to high-dose steroids and other additional immunosuppressants such as tocilizumab and cyclophosphamide might be required in severe, grade 3–4 cases. Recently, increasing research on irAEs after immunotherapy rechallenge has garnered much attention. Dolladille and colleagues assessed the safety in patients with cancer who resumed therapy with the same ICIs and found that rechallenge was associated with about 25–30% of the same irAEs experienced previously (4). However, such data should be carefully considered. Further pooled analyses may be required before we conclude about ICIs’ safety in rechallenge.

Chronic immune-related adverse events arising from immune checkpoint inhibitors: an update

Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review

Achilles' Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach

Facts and Hopes in Prediction, Diagnosis, and Treatment of Immune-Related Adverse Events

Immune-related Adverse Events of Immune Checkpoint Inhibitors: a Review

Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

Acknowledging and addressing real-world challenges to treating immune-related adverse events

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review

Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge

Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Minireview of Current Clinical Guidelines

Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors

Commentary to: Cancer and treatment specific incidence rates of immune related adverse events induced by immune checkpoint inhibitors: a systematic review

Clinical assessment of immune-related adverse events

Management of Immune Checkpoint Inhibitor‐related Adverse Events: A Review of Case Reports

Recommendations And Exploration Of Diagnosis And Treatment Of Critical And Refractory Immune Checkpoint Inhibitor-Associated Adverse Events

Immune-checkpoint inhibitors: long-term implications of toxicity